U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07453849) titled 'TAVR for Aortic Regurgitation Under TEE Guidance' on March 02.
Brief Summary: Under contemporary practice, transcatheter aortic valve replacement (TAVR) is typically performed with fluoroscopic visualization and repeated injections of iodinated contrast. While effective, this paradigm introduces cumulative radiation exposure to both patients and staff and can be problematic in individuals with renal dysfunction, prior contrast reactions, or other situations where contrast use is undesirable. Treating native aortic regurgitation (AR) adds another layer of complexity: limited valvular/annular calcification, enlarged annular dimensions...